Navigation follows, skip to content? New England Baptist Hospital Logo Utility navigation follows, skip to content? Primary navigation follows, skip to content?

Need help finding a doc?

Request a Call Back | Chat Now | Call the Physician Referral Line: 1-855-370-NEBH (6324)

Brian L. Hollenbeck, MD

Chief Medical Officer, Chief, Infectious Disease

New England Baptist Hospital
Phone: 617-754-5900

125 Parker Hill Avenue, Converse Building, 6th Floor
Boston, MA 02120
Fax: 617-738-9602

Brian L. Hollenbeck is Chief of Infectious Disease at New England Baptist Hospital (NEBH). He earned his medical degree from the University of Kansas School of Medicine. After finishing his Internal Medicine Residency and Chief Residency at Brown University, he completed fellowship in Infectious Diseases at Beth Israel Deaconess Medical Center.

Dr. Hollenbeck has research interests in the field of Infection Control/ Hospital Epidemiology and serves as Chair of the NEBH Infection Control Committee.  His research has focused on prevention of surgical site infections after spine surgery.

Dr. Hollenbeck has clinical interest in general infectious diseases, bone and joint infections, and prevention of health-care associated infections. Dr. Hollenbeck is a member of the Massachusetts Medical Society and the Infectious Diseases Society of America.

Academic Affiliations

Clinical Instructor: Harvard Medical School, Medicine

Board Certification

Internal Medicine, Infectious Diseases

Medical Education

Medical School

University of Kansas School of Medicine, 2008


Brown University, 2011


Beth Israel Deaconess Medical Center, 2014


Infectious Disease

Footer navigation follows, return to top?

Our Cookie Policy

Your privacy is important to us. We use cookies and other tracking technologies to ensure the performance and security of our website and to monitor website use for business and website optimization purposes. This may include disclosures about your use of the website to third parties. By using our website, you agree to its use of these technologies. To learn more, please read our Terms of Use.